Santen

Australia’s PolyActiva Opens Fort Worth Office With New Locally Based CEO, CFO, and CSO

by | Jul 17, 2025
After selling Fort Worth-based Eyevance Pharmaceuticals for $225 million in 2020, Jerry St. Peter is back in the company-building business—now as CEO of Melbourne-based PolyActiva. He’s bringing his former top team with him as the company ramps up U.S. clinical trials of its glaucoma treatment.
MORE
Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M
by | Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE